JP2018521030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521030A5 JP2018521030A5 JP2017564358A JP2017564358A JP2018521030A5 JP 2018521030 A5 JP2018521030 A5 JP 2018521030A5 JP 2017564358 A JP2017564358 A JP 2017564358A JP 2017564358 A JP2017564358 A JP 2017564358A JP 2018521030 A5 JP2018521030 A5 JP 2018521030A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- poly
- acid
- methacrylonitrile
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 72
- 230000002163 immunogen Effects 0.000 claims description 66
- 239000002702 enteric coating Substances 0.000 claims description 40
- 238000009505 enteric coating Methods 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 31
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 claims description 29
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 17
- 239000001069 triethyl citrate Substances 0.000 claims description 17
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 17
- 235000013769 triethyl citrate Nutrition 0.000 claims description 17
- 239000000454 talc Substances 0.000 claims description 16
- 229910052623 talc Inorganic materials 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 14
- 229920003139 Eudragit® L 100 Polymers 0.000 claims description 13
- 239000003124 biologic agent Substances 0.000 claims description 12
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 11
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 10
- 210000003405 ileum Anatomy 0.000 claims description 10
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims description 9
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 4
- 241001263478 Norovirus Species 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 241001070941 Castanea Species 0.000 claims description 2
- 235000014036 Castanea Nutrition 0.000 claims description 2
- 101710108545 Viral protein 1 Proteins 0.000 claims description 2
- 239000007891 compressed tablet Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000000034 method Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000008953 bacterial degradation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021113391A JP7269285B2 (ja) | 2015-06-12 | 2021-07-08 | Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175081P | 2015-06-12 | 2015-06-12 | |
| US62/175,081 | 2015-06-12 | ||
| PCT/US2016/036461 WO2016200951A1 (en) | 2015-06-12 | 2016-06-08 | Formulations for small intestinal delivery of rsv and norovirus antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021113391A Division JP7269285B2 (ja) | 2015-06-12 | 2021-07-08 | Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521030A JP2018521030A (ja) | 2018-08-02 |
| JP2018521030A5 true JP2018521030A5 (enExample) | 2020-05-07 |
| JP6912394B2 JP6912394B2 (ja) | 2021-08-04 |
Family
ID=57503876
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564358A Active JP6912394B2 (ja) | 2015-06-12 | 2016-06-08 | Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤 |
| JP2021113391A Active JP7269285B2 (ja) | 2015-06-12 | 2021-07-08 | Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021113391A Active JP7269285B2 (ja) | 2015-06-12 | 2021-07-08 | Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11433146B2 (enExample) |
| EP (2) | EP3307239B1 (enExample) |
| JP (2) | JP6912394B2 (enExample) |
| KR (2) | KR102678401B1 (enExample) |
| CN (2) | CN108024955A (enExample) |
| AU (1) | AU2016274599B2 (enExample) |
| CA (1) | CA2988761A1 (enExample) |
| DK (1) | DK3307239T3 (enExample) |
| EA (1) | EA201792512A1 (enExample) |
| ES (1) | ES2832504T3 (enExample) |
| WO (1) | WO2016200951A1 (enExample) |
| ZA (1) | ZA201708434B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2832504T3 (es) * | 2015-06-12 | 2021-06-10 | Vaxart Inc | Formulaciones para administración de antígenos de norovirus y rsv en el intestino delgado |
| KR20190104051A (ko) * | 2017-01-06 | 2019-09-05 | 스타빌리테크 바이오파마 리미티드 | 바이러스 |
| CN111727255A (zh) * | 2017-11-30 | 2020-09-29 | 麦迪卡格公司 | 修饰后诺如病毒vp1蛋白和包含修饰后诺如病毒vp1蛋白的vlp |
| CN108904795B (zh) * | 2018-08-29 | 2022-07-05 | 温氏食品集团股份有限公司 | 一种猪流行性腹泻病毒的口服疫苗的制备方法 |
| US20210311600A1 (en) * | 2020-04-06 | 2021-10-07 | Kirk David Bacon | Seat Selection Application For Social Distancing Compliance |
| WO2024193965A1 (en) * | 2023-03-17 | 2024-09-26 | Glaxosmithkline Biologicals Sa | Rsv-f-encoding nucleic acids |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152413A (en) | 1978-08-18 | 1979-05-01 | Chromalloy American Corporation | Oral vaccine for swine dysentery and method of use |
| US4520019A (en) | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
| US4579945A (en) | 1982-04-29 | 1986-04-01 | Ribi Immunochem Research, Inc. | Purification of trehalose dimycolates |
| US4505900A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4505899A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436728A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4435386A (en) | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| CA2110899C (en) * | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
| WO1994015635A1 (en) | 1993-01-11 | 1994-07-21 | Dana-Farber Cancer Institute | Inducing cytotoxic t lymphocyte responses |
| US6224911B1 (en) | 1993-03-16 | 2001-05-01 | Syntex (U.S.A.) Llc | Process for the preparation of enteric coated pharmaceutical dosage forms |
| WO1995003035A1 (en) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
| GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| DE69535530D1 (de) | 1994-10-24 | 2007-08-16 | Ophidian Pharm Inc | Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6676935B2 (en) | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
| AU4133397A (en) | 1996-10-28 | 1998-05-22 | Pfizer Inc. | Oral vaccines for young animals with an enteric coating |
| FR2759293B1 (fr) | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
| AUPO856097A0 (en) | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| US6328967B1 (en) | 1998-03-12 | 2001-12-11 | Allergenics, Inc. | Delivery system to modulate immune response |
| GB9818591D0 (en) | 1998-08-27 | 1998-10-21 | Danbiosyst Uk | Pharmaceutical composition |
| US7264771B2 (en) | 1999-04-20 | 2007-09-04 | Baxter International Inc. | Method and apparatus for manipulating pre-sterilized components in an active sterile field |
| US6355270B1 (en) | 1999-01-11 | 2002-03-12 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
| JP2004504264A (ja) | 2000-01-07 | 2004-02-12 | ユニバーシティ オブ シンシナティ | Ｔｈ１又はｔｈ２リンパ球に制御される免疫応答の選択的活性化 |
| AU2003240978A1 (en) | 2002-05-31 | 2003-12-19 | Genteric, Inc. | Multi-functional polyamines for delivery of biologically-active polynucleotides |
| AU2003262922A1 (en) | 2002-08-30 | 2004-03-19 | Genteric, Inc. | Retroductal salivary gland genetic vaccination |
| GB2407500A (en) | 2003-11-03 | 2005-05-04 | Ist Superiore Sanita | Use of microparticles for antigen delivery |
| US20060128653A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| TW200626185A (en) | 2004-12-17 | 2006-08-01 | Bpsi Holdings Inc | Enteric film coating composition containing entericpolymer micronized with detackifier |
| EA014757B1 (ru) * | 2006-02-28 | 2011-02-28 | Вэксарт, Инк. | Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью и выделенная нуклеиновая кислота |
| DE102006060799A1 (de) * | 2006-12-21 | 2008-06-26 | RUHR-UNIVERSITäT BOCHUM | RSV F-Protein und seine Verwendung |
| JP2009298707A (ja) | 2008-06-11 | 2009-12-24 | Ohara Yakuhin Kogyo Kk | 粒子加工方法 |
| JP2011526888A (ja) | 2008-07-01 | 2011-10-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 治療薬を標的送達するための経口速溶性薄膜 |
| US20100221329A1 (en) | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US20120276167A1 (en) | 2009-07-13 | 2012-11-01 | Vaxgene Corporation | Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| DK2477652T3 (en) | 2009-09-16 | 2015-07-20 | Vaxart Inc | Immunization strategy for the prevention of infection H1Ni |
| US20130273154A1 (en) | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| JP2013527753A (ja) * | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
| EP3153578A1 (en) | 2010-07-06 | 2017-04-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| EP2608780B1 (en) | 2010-08-25 | 2018-09-05 | Grant Rufus Sparling II | Improved enteric active substance delivery |
| CN110152000A (zh) | 2011-03-02 | 2019-08-23 | J·深塔格 | 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物 |
| CA3008794C (en) * | 2012-03-29 | 2021-03-16 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| EP3549605A1 (en) | 2012-04-04 | 2019-10-09 | Vaxform LLC | Adjuvant system for oral vaccine administration |
| CA2939581C (en) | 2014-02-20 | 2024-01-23 | Vaxart, Inc. | Formulations for small intestinal delivery |
| ES2832504T3 (es) | 2015-06-12 | 2021-06-10 | Vaxart Inc | Formulaciones para administración de antígenos de norovirus y rsv en el intestino delgado |
-
2016
- 2016-06-08 ES ES16808196T patent/ES2832504T3/es active Active
- 2016-06-08 CN CN201680046440.8A patent/CN108024955A/zh active Pending
- 2016-06-08 KR KR1020187000421A patent/KR102678401B1/ko active Active
- 2016-06-08 DK DK16808196.6T patent/DK3307239T3/da active
- 2016-06-08 KR KR1020247005811A patent/KR102773575B1/ko active Active
- 2016-06-08 CN CN202311287963.XA patent/CN118045170A/zh active Pending
- 2016-06-08 AU AU2016274599A patent/AU2016274599B2/en active Active
- 2016-06-08 EP EP16808196.6A patent/EP3307239B1/en active Active
- 2016-06-08 CA CA2988761A patent/CA2988761A1/en active Pending
- 2016-06-08 US US15/580,651 patent/US11433146B2/en active Active
- 2016-06-08 EA EA201792512A patent/EA201792512A1/ru unknown
- 2016-06-08 EP EP20195995.4A patent/EP3791859A1/en active Pending
- 2016-06-08 JP JP2017564358A patent/JP6912394B2/ja active Active
- 2016-06-08 WO PCT/US2016/036461 patent/WO2016200951A1/en not_active Ceased
-
2017
- 2017-12-12 ZA ZA2017/08434A patent/ZA201708434B/en unknown
-
2021
- 2021-07-08 JP JP2021113391A patent/JP7269285B2/ja active Active
-
2022
- 2022-08-02 US US17/816,788 patent/US12186407B2/en active Active
-
2024
- 2024-11-22 US US18/956,413 patent/US20250082784A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521030A5 (enExample) | ||
| Nollenberger et al. | Poly (meth) acrylate-based coatings | |
| JP5847303B2 (ja) | 医薬品剤形又は機能性食品剤形に適したコーティング組成物 | |
| JP5167345B2 (ja) | 薬剤を加速放出する腸溶コーティングを含む固体剤形 | |
| JP2018500353A5 (enExample) | ||
| JP2009504710A5 (enExample) | ||
| BG105061A (bg) | Ентерично покрит фармацевтичен състав и метод за получаване | |
| JP2008522989A5 (enExample) | ||
| EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
| JP2016532655A5 (enExample) | ||
| CZ223495A3 (en) | Materials for coatings and binding agents for medicament forms and the use of copolymer water dispersions | |
| JP2005320354A5 (enExample) | ||
| BR112013028453B1 (pt) | Uso de uma composição de revestimento, formas de dosagem farmacêuticas ou nutracêuticas gastrorresistentes, e composição do polímero do núcleo/invólucro | |
| KR20130086128A (ko) | 복용 용이성 고형 제제 | |
| JP2015512441A5 (enExample) | ||
| JP2018534280A5 (enExample) | ||
| JP2007524646A (ja) | 膨潤可能なコーティングを有する薬学的組成物 | |
| JPWO2017022248A1 (ja) | 腸溶性カプセル | |
| Tan et al. | Investigation for the quality factors on the tablets containing medicated pellets | |
| JP2017506265A5 (enExample) | ||
| JP5534643B2 (ja) | 多層剤形 | |
| IL272933B2 (en) | Preparation of solid dosage forms comprising antibodies by solution/ suspension layering | |
| AR071970A1 (es) | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla | |
| JP7316268B2 (ja) | 湿式造粒、押出および球形化による抗体を含む固形剤形の調製方法 | |
| HUP0401732A2 (hu) | Kopolimerek használata aktív szerként peptidet és fehérjét tartalmazó galenikus formák előállításához |